Stock analysts at HC Wainwright began coverage on shares of Immuneering (NASDAQ:IMRX – Get Free Report) in a research note issued to investors on Thursday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $14.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 210.42% from the company’s current price.
A number of other research firms also recently weighed in on IMRX. Chardan Capital raised shares of Immuneering to a “strong-buy” rating in a research report on Monday, August 3rd. Oppenheimer reissued an “outperform” rating on shares of Immuneering in a research report on Monday, June 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Immuneering in a research note on Wednesday, June 24th. Needham & Company LLC upped their price objective on shares of Immuneering from $11.00 to $18.00 and gave the stock a “buy” rating in a report on Monday, July 20th. Finally, Wall Street Zen downgraded shares of Immuneering from a “hold” rating to a “sell” rating in a research note on Monday, July 20th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Immuneering presently has an average rating of “Buy” and a consensus price target of $17.50.
View Our Latest Stock Analysis on Immuneering
Immuneering Stock Up 1.1%
Immuneering (NASDAQ:IMRX – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.01). Equities analysts anticipate that Immuneering will post -1.08 EPS for the current year.
Hedge Funds Weigh In On Immuneering
Several large investors have recently modified their holdings of the stock. Focus Financial Network Inc. bought a new position in Immuneering in the 2nd quarter worth about $62,000. PVG Asset Management Corp bought a new stake in Immuneering during the 1st quarter valued at about $773,000. Weiss Asset Management LP bought a new stake in Immuneering during the 1st quarter valued at about $464,000. Cetera Investment Advisers purchased a new position in Immuneering in the first quarter worth about $67,000. Finally, Levin Capital Strategies L.P. purchased a new position in Immuneering in the first quarter worth about $53,000. Hedge funds and other institutional investors own 67.65% of the company’s stock.
About Immuneering
Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.
The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.
Further Reading
- Five stocks we like better than Immuneering
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Immuneering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuneering and related companies with MarketBeat.com's FREE daily email newsletter.
